- Home
- JMSB vs ZURA Comparison
JMSB vs ZURA Comparison
Compare JMSB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | ZURA |
|---|---|---|
| Founded | 2005 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0M | 252.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JMSB | ZURA |
|---|---|---|
| Price | $19.85 | $4.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $22.50 | $11.38 |
| AVG Volume (30 Days) | 17.8K | ★ 767.7K |
| Earning Date | 01-30-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 18.50 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $59,274,000.00 | N/A |
| Revenue This Year | $19.50 | N/A |
| Revenue Next Year | $12.72 | N/A |
| P/E Ratio | $14.17 | ★ N/A |
| Revenue Growth | ★ 11.69 | N/A |
| 52 Week Low | $13.81 | $0.97 |
| 52 Week High | $21.58 | $5.75 |
Technical Indicators
Market Signals| Indicator | JMSB | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 53.01 |
| Support Level | $19.35 | $4.36 |
| Resistance Level | $20.35 | $5.46 |
| Average True Range (ATR) | 0.41 | 0.60 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 41.67 | 37.70 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.